Clinical Trial

Linperlisib Combination With Cyclophosphamide, Prednisone, and Thalidomide (CPT) in R/R NHL

Name: Linperlisib Combination With Cyclophosphamide, Prednisone, and Thalidomide (CPT) in R/R NHL — clinical trial record (NCT07195799)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a multicenter, open-label, non-randomized, multi-cohort study to evaluate the efficacy and safety of linperlisib combined with cyclophosphamide, prednisone, and thalidomide (CPT) regimen in the treatment of relapsed and/or refractory non-Hodgkin lymphoma.

Trial Details

NCT Number	NCT07195799
Lead Sponsor	The First Affiliated Hospital with Nanjing Medical University
Conditions	Non-Hodgkin Lymphoma
Enrollment	180 participants
Start Date	2024-12-31
Primary Completion	2027-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-09-29